⚡ This is your brand? Claim your page FREE and bring it to life on AI search.
Your AEO score measures whether AI search engines (ChatGPT, Claude, Perplexity, Gemini) can actually read your site and cite it in answers. Two-thirds of websites are invisible to them. Explore the use of LENVIMA® in appropriate patients with the following indications just got measured.
4/10 means Explore the use of LENVIMA® in appropriate patients with the following indications is borderline visible. AI bots can crawl your site but your structured-data signals are thin. You are at risk of being skipped when buyers ask AI for a recommendation.
See data on LENVIMA® (lenvatinib) for RAI-R differentiated thyroid cancer, first-line and second-line treatment of advanced renal cell carcinoma, first-line treatment of unresectable hepatocellular carcinoma, and advanced endometrial carcinoma.
Industry: Healthcare
lenvimahcp.com2
Structured Data
6
Content Structure
6
Entity Clarity
3
E-E-A-T Signals
6
Technical AEO
2
AI Discoverability
Is this your brand?
Claim free. You'll see:
Your full 6-category score breakdown
Exact fixes: robots.txt, schema, llms.txt
AI bot crawls from ChatGPT, Claude, Perplexity, Gemini
Personal 50% off code at checkout
In health and wellness, you're not just selling a product. You're asking someone to trust you with their body.
Continue reading in your free Engagemii portalFree signup unlocks the full article plus your personalized AEO fix list for Explore the use of LENVIMA® in appropriate patients with the following indications.
Scored by Engagemii on June 28, 2026. Methodology: engagemii.com/aeo/methodology
Source URL: https://engagemii.com/aeo/brands/lenvimahcp
Cite this score: Engagemii (2026). "AEO Score for Explore the use of LENVIMA® in appropriate patients with the following indications." Retrieved from https://engagemii.com/aeo/brands/lenvimahcp
Licensed under CC BY 4.0. You may reuse this data with attribution: a visible link to engagemii.com.
Powered by Engagemii - AI Brand Discovery and AEO Platform